214 RESULTS
RESEARCH NEWS 2020-04-24 Research News Proponents of LRRK2 inhibitor programs may breathe easier following a paper in the April 22 Science Translational Medicine. A collaboration led by researchers at the Michael J. Fox Foundation found that three different inhibitors of this Par
CONFERENCE COVERAGE 2020-04-22 Conference Coverage Roche and Prothena today announced topline results from the first half of their Phase 2 trial of the α-synuclein antibody prasinezumab. Results were negative on the MDS-UPDRS, the primary outcome measure, but the company said it saw s
CONFERENCE COVERAGE 2020-04-22 Conference Coverage At the second biannual Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD), held virtually April 2 to 5, companies offered some news on investigational Parkinson’s therapies in Phase 1. One approach is targeted
CONFERENCE COVERAGE 2020-04-22 Conference Coverage Certain variants in the TREM2 gene more than triple a person’s risk of AD, seemingly by sapping the protective function this microglial receptor performs. According to findings presented at the virtual AAT-AD/PD meeting, held April 2 t
COMMUNITY NEWS 2020-04-21 Community News Many people with Lewy body diseases (LBDs) such as Parkinson’s ultimately develop dementia, and many have Aβ plaques and tau tangles. Do they have two diseases at the same time, or is this combination of scourges a unique entity unto itself
RESEARCH NEWS 2020-04-17 Research News A meta-analysis of 22 cohorts seems to leave little doubt that variants of the longevity gene klotho protect against dementia—at least in people unfortunate enough to have inherited an ApoE4 allele. Researchers led by Michael Belloy, Stanfor
CONFERENCE COVERAGE 2020-04-16 Conference Coverage At the virtual AAT-AD/PD meeting, held April 2 to 5 online, researchers substantiated some prior hints on potential causal connections between the throngs of bacteria inhabiting the gut, how microglia function in the brain, and deposit
CONFERENCE COVERAGE 2020-04-16 Conference Coverage Three the approved drugs for Alzheimer’s disease attempt to boost the brain’s supply of acetylcholine, a critical neurotransmitter for cognition that wanes in people with the disease. But might crumbling of the brain’s cholinergic syst
CONFERENCE COVERAGE 2020-04-15 Conference Coverage As the Alzheimer’s field branches out its therapeutics search beyond Aβ and tau, some of those approaches are showing glimmers of promise. The second biannual Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD),
CONFERENCE COVERAGE 2020-04-15 Conference Coverage Because cognition in Alzheimer’s disease declines as tangles spread, and tau research tools are finally in hand, researchers are increasingly homing in on tau immunotherapy. At the second biannual Advances in Alzheimer’s and Parkinson’
CONFERENCE COVERAGE 2020-04-10 Conference Coverage At the virtual AAT-AD/PD Focus meeting held April 1 to 5, clinicians and funders involved in the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) fired up their home computers to discuss results from the first DIAN-TU tre
CONFERENCE COVERAGE 2020-04-10 Conference Coverage Against classical music and visual backdrops evoking Vienna, where the second AAT-AD/PD conference was to be held, the meeting instead unfolded Netflix-style. In this surreal age of COVID-19, the conference organizers dropped five days
CONFERENCE COVERAGE 2020-04-10 Conference Coverage A flood of recent data seems to leave little doubt that phospho-tau217 is the better of the soluble tau markers for studying Alzheimer’s disease thus far. At this year’s virtual AAT-AD/PD meeting, Oskar Hansson, Lund University, Sweden
CONFERENCE COVERAGE 2020-04-03 Conference Coverage The conference may be virtual, but the data is real. At the online AAT-ADPD 2020, researchers presented their talks and posters in much that same way as they would have in person—albeit without the open question-and-answer time. Up tod
RESEARCH NEWS 2020-04-01 Research News An aspirin a day does not keep dementia away. Nor does it hedge the risk of mild cognitive impairment or slow decline, according to results published March 25 in Neurology. Reasoning that the anti-inflammatory and cardiovascular health benef
